dr. jon lorsch. thank you. chairman blunt: thank you, dr. collins. we'll start with five-minute rounds and probably have as many rounds as we can while we have this great opportunity to talk to you and what you're doing on precision medicine. obviously, a long path into the future where precision medicine might very well define most medicine at some future point. what would you maybe see as some five and 10-year short-term markers to see getting where we all would like to get as we move towards this precision initiative? dr. collins: i very much appreciate the question. it is something we're all quite excited about. actually we just concluded yesterday, a two-day workshop trying to map out exactly that kind of issue. what kind of uses could a cohort of a million individuals be put to if that were present five years from now? as an example, we really don't at the present time have the ability to take full advantage of what we have learned about individual differences in drug response and see how those work in the real world. the fda has on the label n

dr. doug loewy appointed acting director of the national cancer institute and that are drawn lorsch at theinstitute of general medical sciences. thank you. >> thank you dr. collins. we'll start with five-minute rounds and probably have as many rounds as we can vote at the great opportunity to talk to you in about what you're doing on precision medicine. obviously a long path into the future where precision medicine might well defined most medicine at some future point. what would you see maybe five and 10 year short-term markers to look at to see whether we are getting where we all would like to get as we move towards this precision medicine initiative? >> i very much appreciate the question and something we're all quite excited about and we concluded yesterday a two-day public workshop trained to map out that kind of issue. what kind of uses could a cohort of a million individuals be put to if that was present five years from now. as an example, we really don't at the present time have the ability to take full advantage of open fund about individual differences in drug response and see ho